[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?].

Abstract

Thromboprophylaxis with low molecular weight heparin or fondaparinux is associated with a 50% reduction in the risk of venous thrombo-embolism (VTE) in medical patients. Thromboprophylaxis is indicated in the prevention of VTE in medical patients at risk of VTE. Extended thromboprophylaxis with apixaban is associated with a greater reduction in VTE events but also with an increase in bleeding events when compared to standard therapy with enoxaparine. Extended thromboprophylaxis with rivaroxaban is associated with a greater reduction in VTE events but also with an increase in bleeding events, when compared to standard therapy with enoxaparine. Rivaroxaban and apixaban are currently not indicated in medical prophylaxis.

• Authors: Laurent Bertoletti, Jean-Christophe Lega, Sandrine Accassat, Adel Merah, Patrick Mismetti, Hervé Décousus
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 42 Issue 9 Pt 1 Pg. 1219-24 (Sep 2013) ISSN: 2213-0276 [Electronic] France
• Vernacular Title: Thromboprophylaxie en médecine : quelles modifications avec les nouveaux anticoagulants oraux ?
• PMID: 23886928 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anticoagulants
• Enoxaparin
• Morpholines
• Pyrazoles
• Pyridones
• Thiophenes
• apixaban
• Rivaroxaban

Topics

• Administration, Oral
• Anticoagulants (administration & dosage)
• Enoxaparin (administration & dosage)
• Humans
• Morpholines (administration & dosage)
• Pyrazoles (administration & dosage)
• Pyridones (administration & dosage)
• Rivaroxaban
• Thiophenes (administration & dosage)
• Thromboembolism (prevention & control)